Clinical Trial Update: Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and effectiveness of PDA001 (human placenta-derived cells) for ischemic stroke was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• PDA001

Snippet

Sponsor: Celularity Incorporated | Conditions: Stroke, Acute, Middle Cerebral Artery Stroke | Phase 2 | Status: TERMINATED